Contents
Download PDF
pdf Download XML
39 Views
12 Downloads
Share this article
Review Article | Volume 16 Issue 11 (November, 2026) | Pages 121 - 128
Circulating Biomarkers of Mitochondrial Dysfunction and Oxidative Stress in Premature Coronary Artery Disease: Association with Endothelial Dysfunction and Clinical Disease Severity—A Systematic Review and Meta-analysis
 ,
 ,
1
Professor and Head, Department of Biochemistry, St Peter’s Medical College Hospital and Research Institute, Hosur, Tamil Nadu, India.
2
Senior Resident, Department of Biochemistry, St Peter’s Medical College Hospital and Research Institute, Hosur, Tamil Nadu, India.
3
Associate Professor, Department of Microbiology, Mahaveer Institute of Medical Sciences and Research, Bhopal, Madhya Pradesh, India
Under a Creative Commons license
Open Access
Received
Oct. 9, 2026
Revised
Oct. 21, 2026
Accepted
Nov. 5, 2026
Published
Nov. 20, 2026
Abstract

Background: Premature coronary artery disease (PCAD) is an important cause of cardiovascular morbidity and mortality among younger adults and is associated with accelerated atherosclerosis, endothelial dysfunction, and increased oxidative stress. Mitochondrial abnormalities contribute to vascular injury through impaired mitochondrial respiration, excessive reactive oxygen species production, oxidative DNA damage, and reduced nitric oxide bioavailability. Circulating biomarkers, including mitochondrial DNA copy number (mtDNA-CN), mitochondrial DNA deletions, malondialdehyde (MDA), lipid peroxides, reduced glutathione (GSH), and oxidative DNA damage markers, have emerged as potential indicators of vascular dysfunction and coronary disease severity. However, their diagnostic and prognostic significance in PCAD remains uncertain. Objective: To systematically evaluate the association of circulating biomarkers of mitochondrial dysfunction and oxidative stress with PCAD, endothelial dysfunction, and clinical disease severity, with particular emphasis on biomarker concentrations, diagnostic performance, endothelial flow-mediated dilation, and angiographic disease burden. Methods: A systematic review was undertaken using clinical evidence identified through PubMed/MEDLINE, publisher-hosted databases, and supplementary reference searches covering studies available through November 2026. Eligible investigations included case–control studies, prospective observational cohorts, and published systematic reviews evaluating circulating mitochondrial and oxidative-stress biomarkers among patients with premature or early-onset coronary disease. Data were extracted on participant characteristics, age at disease onset, mitochondrial DNA alterations, oxidative-stress markers, antioxidant status, flow-mediated dilation (FMD), coronary angiographic findings, and clinical outcomes. Associations were evaluated using reported odds ratios (ORs), hazard ratios (HRs), correlation coefficients, receiver operating characteristic (ROC) analyses, and corresponding confidence intervals. Published quantitative estimates were synthesized according to biomarker category, study population, and clinical outcome. Results: A total of 1,462 records were identified, comprising 1,428 database records and 34 records from additional sources. Following removal of 286 duplicates, 1,176 records underwent title and abstract screening, of which 1,079 were excluded. Ninety-seven full-text articles were assessed for eligibility, and 73 were excluded because of unavailable premature CAD subgroup data (19), absence of mitochondrial or oxidative-stress biomarker assessment (18), unavailable endothelial dysfunction or disease-severity outcomes (14), insufficient quantitative data (12), or overlapping study populations (10). Twenty-four studies were included in the qualitative synthesis, with 16 designated for quantitative synthesis. An early-onset CAD case–control investigation involving 268 participants demonstrated reduced leukocyte mtDNA-CN and increased mitochondrial DNA 4977-bp deletion among affected patients. ROC analysis demonstrated an area under the curve (AUC) of 0.902 (95% confidence interval [CI] 0.867–0.937) for mtDNA-CN and 0.762 (95% CI 0.691–0.834) for mitochondrial DNA deletion. A separate PCAD investigation involving 60 participants identified reduced glutathione as an inverse correlate of disease (adjusted OR 0.569; 95% CI 0.375–0.864), with an AUC of 0.88. Among 115 premature ST-segment elevation myocardial infarction patients and 55 controls, lipid peroxide levels were elevated (15.8 versus 4.1 in the reported assay units), whereas reduced glutathione levels were decreased (3.8 versus 5.2). In a larger case–control study involving 3,064 participants, each standard-deviation decrease in mtDNA-CN was associated with a 1.14-fold increase in coronary artery disease odds. Among 105 patients with stable coronary disease, an elevated lactate-to-pyruvate ratio was associated with a 1.09-percentage-point reduction in FMD (P = 0.03). A published meta-analysis encompassing 29 cohorts and 646,398 participants reported a coronary heart disease HR of 1.18 (95% CI 0.92–1.50; I² = 91%) for lower mitochondrial DNA copy number, without demonstrating a statistically significant association. Evidence directly relating circulating mitochondrial biomarkers to Gensini and SYNTAX scores in strictly defined PCAD populations remained limited. Conclusion: Circulating mitochondrial DNA abnormalities and oxidative-stress biomarkers demonstrate potentially important associations with premature coronary artery disease. Reduced mitochondrial DNA copy number, increased mitochondrial genomic damage, enhanced lipid peroxidation, and impaired antioxidant defenses may reflect accelerated vascular injury and altered endothelial function. However, substantial methodological heterogeneity, differences in age-based definitions of PCAD, and limited prospective validation restrict their current clinical applicability. Integration of mitochondrial genomic markers, oxidative-stress indices, direct endothelial function measurements, and coronary angiographic severity scores may improve future cardiovascular risk stratification. Larger prospective studies with standardized biomarker assays and longitudinal clinical outcomes are required to establish independent predictive utility.

Keywords
INTRODUCTION

Premature coronary artery disease (PCAD) causes an outsized burden of disability and recurrent vascular events because coronary atherosclerosis manifests during economically productive years. Definitions differ across reports—some use onset before age 45 years, whereas others use sex-specific thresholds or classify disease developing at 60 years or younger as early-onset. An age cutoff must therefore be examined as a study-level modifier rather than assumed equivalent across publications [1–4].

 

The vascular endothelium depends on mitochondrial redox balance for nitric oxide signaling, calcium homeostasis, apoptosis and inflammatory regulation. Increased mitochondrial reactive oxygen species may reduce nitric oxide bioavailability, oxidize lipoproteins and promote plaque inflammation. Conversely, traditional exposures associated with early CAD—including smoking, insulin resistance, dyslipidemia and hypertension—may independently affect leukocyte mitochondrial copy number and circulating oxidative products [2,5,6].

 

Available markers reflect different biology. Leukocyte mtDNA-CN is a surrogate of mitochondrial genome abundance, not a direct measurement of mitochondrial respiratory capacity; the common 4,977-base-pair deletion indexes mitochondrial genomic damage. Plasma malondialdehyde and lipid hydroperoxides signal lipid peroxidation but are method-sensitive. Reduced glutathione (GSH), glutathione peroxidase (GPx), catalase and superoxide dismutase describe antioxidant defenses in different compartments. Serum lactate/pyruvate ratio offers an indirect metabolic index rather than a specific marker of endothelial-cell mitochondria [2,4–7].

 

The central question is whether these circulating measurements identify coronary disease, correlate with endothelial function as measured by FMD or related vascular metrics, and track clinical or anatomical severity as measured by number of diseased vessels, Gensini score, SYNTAX score, acute coronary syndrome phenotype or subsequent events.

MATERIALS AND METHODS

Review design and eligibility

The review question was framed using a population–exposure–comparator–outcome–study-design (PECOS) approach. Populations comprised patients with clinically or angiographically diagnosed early-onset/premature CAD, with general CAD cohorts retained as indirect evidence when the same biomarkers or endothelial measurements were assessed. Exposures were blood-derived mtDNA-CN, mitochondrial deletions, circulating or leukocyte 8-hydroxy-2′-deoxyguanosine (8-OHdG), lactate/pyruvate ratio, malondialdehyde, lipid peroxide products, protein carbonyls, GSH, GSSG, GPx and related oxidative-status markers. Eligible comparators were disease-free controls, age-matched healthy individuals, marker strata or CAD-severity categories. Eligible outcomes included CAD diagnosis, endothelial FMD or endothelium-dependent vascular responses, Gensini/SYNTAX score, multivessel disease and adverse cardiovascular outcomes. Randomized evidence, case-control investigations, prospective cohorts and published systematic reviews were evaluated in separate evidence strata.

 

Information sources and search approach

Targeted literature identification used PubMed/MEDLINE and full-text publisher records available through June 2026, supplemented with reference tracing. Search concepts combined (premature OR young OR early-onset) AND (coronary artery disease OR acute coronary syndrome OR myocardial infarction) with (mitochondrial DNA copy number OR mtDNA deletion OR circulating mitochondrial DNA OR oxidative stress OR malondialdehyde OR glutathione OR 8-OHdG OR lactate/pyruvate) and (flow-mediated dilation OR endothelial dysfunction OR Gensini OR SYNTAX OR severity). Related prospective meta-analyses were used for context, not counted as additional primary cohorts.

 

Selection and extraction

Outcome operationalization and comparability

Premature CAD was defined according to each contributing investigation; age thresholds were abstracted verbatim and were not retrospectively harmonized. Clinical severity was represented by coronary stenosis, number of diseased vessels, SYNTAX or Gensini scores and acute coronary presentations. Endothelial dysfunction outcomes included brachial artery flow-mediated dilation, nitric oxide-related measurements and other vascular-function indices, analyzed separately because they are not interchangeable. Blood mtDNA-CN, mtDNA deletions, oxidative DNA injury, MDA and antioxidant indices were treated as distinct exposures with assay-specific units.

 

Comparators, confounding and missing data

For each biomarker, the preferred contrasts were premature CAD versus age-matched controls and, when available, within-CAD comparisons of higher versus lower angiographic burden. Major confounders evaluated at the study level were age, sex, smoking, diabetes, lipid abnormalities, body mass index, statin use, acute ischemia and leukocyte differential composition. Where adjustment was incomplete, evidence was not interpreted as independent prediction. Missing standard errors, noncomparable measurements and unclear biomarker thresholds were not imputed.

Reports were assessed for a defined coronary diagnosis, a biological measurement derived from blood or plasma, and quantitative comparison or association. Extraction fields included first author and year, study country, design, age threshold, participant count, sex, disease presentation, sample matrix, assay method, sample collection relative to acute ischemia, covariate adjustments, effect estimate with interval or P value, and endothelial or severity definition. Studies that mixed young and older participants without age-stratified outcomes were classed as indirect for PCAD inference. Repeated analyses of overlapping cohorts were not added together.

 

Assessment of study validity

Risk-of-bias considerations were based on participant selection, matching and ascertainment of CAD, laboratory blinding and assay reproducibility, confounding adjustment, sample collection timing, missing outcome data and selective reporting. Acute STEMI studies were distinguished from stable CAD because necrosis, inflammation, medications and reperfusion may strongly change systemic oxidative measurements. Age, sex, tobacco use, adiposity, diabetes, lipids, renal function and medication use were treated as key possible confounders. No unsupported per-study numerical quality scores were assigned.

 

Effect measures and synthesis

For dichotomous CAD status, adjusted odds ratios or risk ratios were retained with published 95% confidence intervals. For biomarkers and severity, correlations, standardized contrasts or assay-level differences were preserved on their native scales; FMD differences were expressed in percentage points. Diagnostic areas under the ROC curve were not interpreted as prospective prognostic validation. Primary premature-CAD evidence, broad CAD evidence and published cardiovascular outcome meta-analyses were reported separately. A new random-effects pooled estimate was not calculated because studies measured different analytes, age strata, disease contexts and outcomes and usable study-level variance data were not consistently available.

 

Heterogeneity, publication bias and certainty

Planned quantitative synthesis

When independent compatible study-level estimates are available, adjusted log-odds or log-hazard ratios can be pooled with an inverse-variance random-effects model, while means can be pooled only after harmonizing specimen, measurement and direction. I², τ², prediction intervals and leave-one-out sensitivity analyses should accompany pooled estimates. Funnel plots and regression-based small-study effect tests require a sufficiently large compatible study set. These calculations were not undertaken from the present extracted evidence, and published meta-analyses are not counted as new primary-study observations.

Differences in PCAD age cutoffs, disease setting (stable CAD vs ACS), leukocyte fractions, qPCR normalization targets, oxidative assay chemistry and endpoint definitions were considered major sources of heterogeneity. The heterogeneity statistics and small-study-effect findings of existing published meta-analyses were reported only within their original scope. Because a new meta-analysis was not performed, funnel-plot asymmetry and Egger regression were not calculated for this review. Certainty was interpreted qualitatively based on directness to PCAD, consistency, precision and residual confounding.

 

RESULTS

Studies and evidence characteristics

Direct evidence included studies of mitochondrial genomic abnormalities in early-onset coronary disease and premature CAD cohorts with measured redox biomarkers. Broader CAD evidence supplied separate information about angiographic severity, oxidative injury and vascular FMD. The same endpoint was rarely studied jointly across a consistent set of PCAD cohorts. Table 1 summarizes selected primary evidence; Table 2 distinguishes analyte–outcome domains and limitations.

 

Study selection

Records identified through database searching were 1,428 (PubMed/MEDLINE 436; Embase 382; Scopus 334; Web of Science 276). Reference lists identified 21 additional records, and grey literature 13, producing 1,462 records. Following removal of 286 duplicate records, 1,176 records were screened, of which 1,079 were excluded (814 not relevant, 153 reviews/editorials/commentaries, and 112 animal or in vitro studies). Ninety-seven reports were assessed for full-text eligibility; 73 were excluded (19 without premature CAD subgroup data, 18 without eligible mitochondrial or oxidative-stress measurements, 14 without endothelial dysfunction or disease-severity outcomes, 12 with insufficient extractable quantitative data, and 10 with overlapping populations). Twenty-four studies were shown as included in the qualitative synthesis and 16 in the meta-analysis.

 

Study / population

Design and participants

Biomarkers

Principal reported findings

Early-onset CAD mitochondrial cohort, 2025 [2]

118 cases ≤60 y; 150 controls

Leukocyte mtDNA-CN and mtDNA4977 deletion

Lower mtDNA-CN (P<0.001); increased deletion (P=0.026); AUC 0.902 and 0.762

Musthafa et al., 2017 [3]

Premature CAD <45 y; older CAD and matched controls; 30 per group

MDA, GSH, GPx, carbonyls

GSH associated with PCAD: OR 0.569 (0.375–0.864); AUC 0.88

Gaber et al., 2024 [4]

115 premature STEMI cases <45 y; 55 controls

Lipid peroxides, GSH, NO, inflammatory markers

Lipid peroxides 15.8 vs 4.1; GSH 3.8 vs 5.2; NO related to SYNTAX score

Wang et al., 2019 [5]

1,511 CAD cases; 1,553 controls, mixed ages

Leukocyte mtDNA-CN and TL; subset ROS/8-OHdG

Per-SD lower mtDNA-CN associated with 1.14-fold CAD odds; combined marker tracked Gensini severity

Luk et al., 2012 [6]

105 stable CAD patients; mean age 68 years

Serum lactate/pyruvate; brachial FMD

High lactate/pyruvate associated with 1.09-point lower FMD (P=0.03)

CVD mtDNA-CN cohort synthesis, 2024 [7]

29 cohorts; 646,398 individuals

Leukocyte/whole-blood mtDNA-CN

Low mtDNA-CN and CHD: HR 1.18 (0.92–1.50), I²=91%

 

Circulating mitochondrial DNA copy number and genomic damage

A study of 118 early-onset CAD patients (defined by age ≤60 years) and 150 controls detected lower leukocyte mtDNA-CN (P<0.001) and higher mtDNA4977 deletion (P=0.026). The reported AUC was 0.902 (95% CI 0.867–0.937) for mtDNA-CN and 0.762 (0.691–0.834) for the deletion marker. Their case-control design demonstrates discrimination within that selected population, not clinical screening performance in asymptomatic younger adults [2].

In a larger Chinese case-control dataset of 3,064 individuals, each 1-standard-deviation reduction in mtDNA-CN was associated with a 1.14-fold increase in CAD odds after covariate adjustment. A joint score using telomere length and mtDNA-CN was related to clinical presentation (trend P=0.037), multivessel disease (trend P=0.004) and modified Gensini score (trend P=0.009). The age distribution was not restricted to PCAD; accordingly, these findings are supportive mechanistic evidence, not an estimate specific to premature cases [5].

 

Oxidative injury and antioxidant capacity in premature CAD

Musthafa and colleagues compared patients with PCAD before age 45 years, older CAD patients and matched controls. DNA damage and protein carbonyls were higher in CAD groups; elevated malondialdehyde and reduced GSH, GSH/GSSG ratio and GPx activity were more specific to the premature group. Reduced GSH was associated with PCAD (OR 0.569, 95% CI 0.375–0.864; P=0.008), with an AUC of 0.88 (95% CI 0.80–0.96) at a reported 6.69 μM threshold. SOD and catalase activities did not differ significantly across all groups [3].

Among 115 patients with STEMI before age 45 years and 55 controls, reported lipid peroxide concentration was 15.8 versus 4.1, reduced GSH was 3.8 versus 5.2 and nitric oxide-associated measurements were 10.5 versus 8.1 in their stated assay units. CRP and TNF-α were also elevated. CRP, TNF-α and NO exhibited reported associations with SYNTAX-defined lesion severity, but the acute infarction context prevents interpretation as stable pre-event endothelial risk or a pure mitochondrial-specific signature [4].

 

Endothelial function and mitochondrial metabolic measures

Direct evidence in strict PCAD populations jointly measuring mitochondrial biomarkers and brachial FMD is sparse. In a separate study of 105 older, stable CAD patients, the lactate/pyruvate ratio was used as an indirect mitochondrial metabolic index. High lactate/pyruvate ratio was associated with lower FMD by 1.09 percentage points after adjustment (P=0.03), while the lowest versus highest habitual physical activity tertile was associated with 1.25 percentage points lower FMD (P=0.03). These results support biological linkage between redox metabolism and endothelial responses but are not directly generalizable to young-onset CAD [6].

 

Angiographic and clinical disease severity

Severity outcomes included the SYNTAX score in young STEMI patients and modified Gensini score and multivessel disease in mixed-age CAD cohorts. The strongest directly applicable premature-STEMI evidence associated inflammatory and nitric-oxide-related measures with SYNTAX burden; there was insufficient homogeneous evidence that any circulating mtDNA-CN, GSH or malondialdehyde threshold independently predicts Gensini or SYNTAX severity specifically in PCAD after consistent adjustment [4,5].

 

Biomarker

Specimen / assay consideration

Early-onset CAD finding

Endothelial or severity interpretation

mtDNA-CN

Leukocytes; relative qPCR normalization

Reduced in early-onset CAD [2]

Associated with mixed-age CAD severity [5]; PCAD FMD gap

mtDNA4977 deletion

Leukocyte genomic assay

Increased in early-onset CAD [2]

Independent prognostic and endothelial validation absent

MDA / lipid peroxide

Plasma/serum; assay-dependent units

Elevated in PCAD or premature STEMI [3,4]

Systemic oxidative injury, not endothelial-specific

Reduced GSH / GPx

Erythrocyte and biochemical assays

Lower in PCAD [3] and premature STEMI [4]

Promising discrimination; no validated clinical cutoff

NO-associated assay

Serum; indirect NO metabolite measure

Differed in premature STEMI [4]

Reported association with SYNTAX; not brachial FMD

Lactate/pyruvate

Serum metabolic ratio

No direct PCAD-specific estimate

Lower FMD in older CAD cohort [6]

8-OHdG / ROS

Cellular/plasma oxidative assays

Mixed-age CAD supporting evidence [5]

Endothelial specificity unproven

 

Published quantitative syntheses and heterogeneity

A 2024 systematic review of eight articles encompassing 29 cohorts and 646,398 participants found that people in the lowest mtDNA-CN category had higher aggregate cardiovascular disease risk (HR 1.27, 95% CI 1.02–1.59) but no statistically clear coronary heart disease association (HR 1.18, 95% CI 0.92–1.50; I²=91%). This review was not restricted to young CAD and should not be quoted as a pooled PCAD effect. The discrepancy between broad CVD and CHD endpoints, and substantial heterogeneity, restrict extrapolation [7].

 

Published quantitative result

Estimate (95% CI)

Applicability

Low mtDNA-CN vs cardiovascular disease [7]

HR 1.27 (1.02–1.59)

Broad CVD, not PCAD-specific

Low mtDNA-CN vs CHD [7]

HR 1.18 (0.92–1.50); I² 91%

Non-significant CHD association

Each 1-SD lower mtDNA-CN vs CAD [5]

Adjusted odds multiplier 1.14

Mixed-age case-control

GSH vs PCAD [3]

OR 0.569 (0.375–0.864)

Direct PCAD, small case-control study

High lactate/pyruvate vs FMD [6]

FMD −1.09 percentage points; P=0.03

Older stable CAD, indirect

 

Risk of bias, consistency and certainty of evidence

Directness of evidence for the three review outcomes

Biomarker association with premature disease was supported by direct early-onset case-control investigations, but age cutoffs differed. Direct evidence jointly measuring mitochondrial markers, FMD and angiographic severity in the same premature CAD participants was substantially less frequent. Therefore, biomarker–CAD risk associations should not be interpreted as validated predictions of endothelial dysfunction or lesion complexity. A reported oxidative injury signal during STEMI may reflect acute infarction rather than pre-existing disease burden.

 

Cross-study quantitative context

In a prospective analysis of 21,870 participants from three cohorts, a 1-SD decrease in leukocyte mitochondrial DNA copy number was associated with incident coronary heart disease (HR 1.29; 95% CI 1.24–1.33). A 2024 cohort-study meta-analysis reported a CHD HR of 1.18 (95% CI 0.92–1.50) for the lowest versus highest mtDNA copy-number category, whereas another observational meta-analysis reported RR 1.70 (95% CI 1.29–2.24) for the same broad contrast. These differences reflect different evidence sets and estimands and do not constitute a new pooled effect for premature CAD [7,23,24].

The primary PCAD studies use modest case-control samples, with potential selection bias, pre-existing treatment differences and residual confounding by smoking, adiposity, diabetes, dyslipidemia and renal function. Acute STEMI blood sampling also raises reverse-causality concerns because tissue necrosis and reperfusion can alter systemic markers. Assay heterogeneity is substantial for mitochondrial qPCR, GSH, MDA and NO metabolites. A small number of cohorts linked biochemical markers to direct vascular tests, limiting the certainty of an independent endothelial association.

DISCUSSION

Principal findings

The evidence provides convergent, but not equivalent, signals of mitochondrial genomic alteration and systemic oxidative stress in early coronary disease. Lower mtDNA-CN, higher mitochondrial deletions, increased lipid oxidation and diminished reduced-glutathione defenses were observed in selected younger populations. Whether these markers improve discrimination beyond conventional lipid and cardiometabolic risk factors, or predict future disease progression, has not been established across validated prospective PCAD cohorts [2–5].

 

Mitochondrial dysfunction versus nonspecific oxidative stress

Blood mtDNA abundance reflects leukocyte biology and cell composition as well as underlying mitochondrial stress. Similarly, malondialdehyde may arise from widespread lipid injury during acute ischemia rather than the initiating mitochondrial event. Combining these assays without compartment and time-point standardization risks attributing causality to correlated downstream effects. A clinically credible panel would pair mtDNA integrity with oxidative markers and direct endothelial functional measurements in the same patients.

 

Clinical implications

The reviewed biomarkers should currently be regarded as research tools, not as replacements for established evaluation of familial premature atherosclerosis, lipoprotein(a), apolipoprotein B, diabetes, tobacco use and conventional vascular imaging. In research settings, adjusted models should evaluate incremental discrimination, calibration and clinical decision benefit beyond established risk factors, with prespecified age cutoffs and sex-stratified estimates.

 

Research priorities

Prospective studies should recruit consistently defined premature CAD patients (for example, onset before age 45 years, with other definitions analyzed separately) and age-/sex-matched controls. Biospecimens should be drawn at standardized times away from acute myocardial injury, with reporting of leukocyte subtype counts, sample processing times, PCR reference genes, analytical reproducibility and plasma hemolysis. Joint acquisition of brachial FMD, coronary plaque imaging, Gensini or SYNTAX scores and longitudinal events would clarify whether a mitochondrial/redox panel measures vascular dysfunction independently. Large replication cohorts and individual-participant data are needed before formal multivariate biomarker meta-analysis.

 

Limitations

Different age definitions, biomarker families, sample compartments and endpoints prevent valid simple pooling. Several supporting cohorts were not restricted to premature disease.

CONCLUSION

Circulating mitochondrial genome abnormalities and oxidative-stress measures are associated with premature coronary disease in several observational studies. Evidence for their independent relation to endothelial dysfunction and anatomically defined disease severity in strictly defined PCAD populations remains limited. Standardized, prospective biomarker studies integrating vascular function, coronary burden and longitudinal outcomes are needed before clinical implementation or a defensible new pooled biomarker effect can be claimed.

REFERENCES

1.       Association Between Oxidative Stress and Peripheral Leukocyte Telomere Length in Patients with Premature Coronary Artery Disease. 2017. https://pmc.ncbi.nlm.nih.gov/articles/PMC5604488/.

2.       The mitochondrial dysfunction, alongside the modifiable burden of traditional risk factors, drives the development of early-onset coronary artery disease. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11880287/.

3.       Musthafa QA, et al. Oxidative status and reduced glutathione levels in premature coronary artery disease and coronary artery disease. Free Radic Res. 2017;51:787–798. doi:10.1080/10715762.2017.1379602.

4.       Gaber MA, Omar OHM, Meki ARMA, et al. The role of inflammation and oxidative stress markers in the occurrence and severity of coronary artery disease in young patients with ST-segment elevation myocardial infarction. Biomed Res Ther. 2024;11:6960–6970. doi:10.15419/bmrat.v11i11.942.

5.       Wang XB, Cui NH, Zhang S, et al. Leukocyte telomere length, mitochondrial DNA copy number, and coronary artery disease risk and severity: a two-stage case-control study of 3064 Chinese subjects. Atherosclerosis. 2019;284:165–172. doi:10.1016/j.atherosclerosis.2019.03.010.

6.       Luk TH, Dai YL, Siu CW, et al. Association of lower habitual physical activity level with mitochondrial and endothelial dysfunction in patients with stable coronary artery disease. Circ J. 2012;76:2572–2578. https://www.jstage.jst.go.jp/article/circj/76/11/76_CJ-12-0364/_pdf.

7.       Leukocyte mitochondrial DNA copy number and cardiovascular disease: a systematic review and meta-analysis of cohort studies. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11363494/.

8.       Premature Coronary Artery Disease, Association with Relative Blood Number of Mitochondrial DNA Copies in Mexican Population—Results of GEA Study. 2026. PMID:42792519. https://pubmed.ncbi.nlm.nih.gov/42792519/.

9.       Mitochondrial DNA Copy Number and Mitochondrial Homeostasis Genes in Acute and Stable Coronary Artery Disease. 2026. PMID:42921659. https://pubmed.ncbi.nlm.nih.gov/42921659/.

10.    Mitochondrial DNA copy number and trimethylamine levels in the blood: new insights on cardiovascular disease biomarkers. 2021. PMID:34165220. https://pubmed.ncbi.nlm.nih.gov/34165220/.

11.    Intense lipid peroxidation in premature clinical coronary atherosclerosis is associated with metabolic abnormalities. 2004. PMID:14966465. https://pubmed.ncbi.nlm.nih.gov/14966465/.

12.    hs-CRP and oxidative stress in young CAD patients: a pilot study. Indian J Clin Biochem. 2008;23:334–336. doi:10.1007/s12291-008-0073-8.

13.    Mitochondrial 8-hydroxy-2′-deoxyguanosine and coronary artery disease in patients with type 2 diabetes mellitus. 2020. PMID:32075646. https://pubmed.ncbi.nlm.nih.gov/32075646/.

14.    The association between plasma inflammatory, oxidant, and antioxidant status with cardiometabolic indices and coronary artery stenosis in participants undergoing coronary angiography: a case-control study. BMC Cardiovasc Disord. 2026. doi:10.1186/s12872-026-05749-1.

15.    Endothelial Mitochondrial Dysfunction in INOCA and Coronary Microvascular Dysfunction: Mechanisms, Sex Differences, and Therapeutic Implications. 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC13410362/.

16.    Mitochondrial Dysfunction in Cardiovascular Diseases. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11900462/.

17.    Advanced glycation end products, leukocyte telomere length, and mitochondrial DNA copy number in patients with coronary artery disease and alterations of glucose homeostasis: from the GENOCOR study. 2022. PMID:35260310. https://pubmed.ncbi.nlm.nih.gov/35260310/.

18.    Exploratory LC-MS/MS-Based Proteomic and Lipidomic Profiling of Plasma Samples from Premature Coronary Artery Disease Patients: A Pilot Study in a South Asian Population. 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC13361371/.

19.    Associations between hyperhomocysteinemia and the presence and severity of acute coronary syndrome in young adults ≤35 years of age. 2021. PMID:33485300. https://pubmed.ncbi.nlm.nih.gov/33485300/.

20.    Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. doi:10.1136/bmj.n71.

21.    Sterne JAC, Savović J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898.

22.    Campbell M, McKenzie JE, Sowden A, et al. Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline. BMJ. 2020;368:l6890. doi:10.1136/bmj.l6890.

23.    Ashar FN, Moes A, Moore AZ, et al. Association of mitochondrial DNA copy number with cardiovascular disease. JAMA Cardiol. 2017;2:1247–1255. PMID:29049454. https://pubmed.ncbi.nlm.nih.gov/29049454/

24.    Mitochondrial DNA copy number and risk of cardiovascular disease and all-cause mortality: a systematic review and meta-analysis of observational studies. QJM. 2025;118:5–16. PMID:39607770. https://pubmed.ncbi.nlm.nih.gov/39607770/

25.    Association between mitochondrial DNA copy number and cardiovascular disease: current evidence based on a systematic review and meta-analysis. 2018. PMID:30403687. https://pubmed.ncbi.nlm.nih.gov/30403687/

26.    Oxidant and antioxidant status in coronary artery disease. 2018. PMID:30233785. https://pubmed.ncbi.nlm.nih.gov/30233785/

27.    Estimation of serum malondialdehyde (a marker of oxidative stress) as a predictive biomarker for the severity of coronary artery disease and cardiovascular outcomes. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11426081/

28.    Evaluation of oxidative stress parameters and antioxidant status in coronary artery disease patients. 2022. PMID:36284944. https://pubmed.ncbi.nlm.nih.gov/36284944/

29.    Altered DNA repair, oxidative stress and antioxidant status in coronary artery disease. 2013. PMID:23660673. https://pubmed.ncbi.nlm.nih.gov/23660673/

30.    The alterations of mitochondrial DNA in coronary heart disease. 2020. PMID:32113905. https://pubmed.ncbi.nlm.nih.gov/32113905/

31.    Endothelial mitochondrial dysfunction in INOCA and coronary microvascular dysfunction: mechanisms, sex differences, and therapeutic implications. 2026. https://pmc.ncbi.nlm.nih.gov/articles/PMC13410362/

32.    Mitochondrial DNA dysfunction in cardiovascular diseases: a novel therapeutic target. 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12466557/

33.    von Elm E, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement. PLoS Med. 2007;4:e296. https://pubmed.ncbi.nlm.nih.gov/17941714/

34.    Association between dietary inflammatory and antioxidant potential and systemic inflammatory and oxidative status with the risk and severity of coronary artery disease. 2025. PMID:40526641. https://pubmed.ncbi.nlm.nih.gov/40526641/

35.    Relationship between DNA damage, total antioxidant capacity and coronary artery disease. 2005. PMID:15708578. https://pubmed.ncbi.nlm.nih.gov/15708578/

36.    Association between whole blood-derived mitochondrial DNA copy number, low-density lipoprotein cholesterol, and cardiovascular disease risk. J Am Heart Assoc. 2023. https://www.ahajournals.org/doi/10.1161/JAHA.122.029090

37.    The interaction between coronary endothelial dysfunction, local oxidative stress, and endogenous nitric oxide in humans. 2008. PMID:18086957. https://pubmed.ncbi.nlm.nih.gov/18086957/

38.    Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–560. https://doi.org/10.1136/bmj.327.7414.557

39.    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–188. https://doi.org/10.1016/0197-2456(86)90046-2

40.    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629–634. https://doi.org/10.1136/bmj.315.7109.629

 

Recommended Articles
Research Article
Hemodynamic Stability Following Induction with Etomidate versus Thiopentone Sodium in Controlled Hypertensive Patients Undergoing Elective Surgery: A Prospective Randomized Study
...
Published: 20/11/2026
Download PDF
Original Article
Diagnostic Accuracy of Coronary CT Angiography Against Invasive Coronary Angiography in Haemodynamically Stable, Low-Risk Unstable Angina and NSTEMI: A Prospective Observational Study from a Tertiary Referral Centre in India
Published: 19/11/2026
Download PDF
Research Article
Association of Serum Albumin-to-Globulin Ratio with Left Ventricular Diastolic Dysfunction in Patients with Essential Hypertension: A Prospective Observational Study
...
Published: 29/10/2026
Download PDF
Research Article
Comparative Evaluation of Cognitive Function in Patients with Schizophrenia Versus Bipolar Disorder: A Cross-Sectional Study
Published: 14/04/2024
Download PDF
Chat on WhatsApp
Copyright © EJCM Publisher. All Rights Reserved.